Allergy Diagnostics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2025-2034

The Global Allergy Diagnostics Market was valued at USD 5.6 billion in 2024 and is poised to grow at a CAGR of 9.2% between 2025 and 2034. Allergy diagnostics focuses on a range of tests, services, and technologies designed to identify specific allergens responsible for allergic reactions in patients. These solutions are vital for the detection of various allergic disorders, including food allergies, respiratory allergies, and drug allergies. The increasing prevalence of allergic conditions worldwide, driven by environmental changes, pollution, and lifestyle shifts, is significantly fueling market expansion. Furthermore, rising awareness about allergy diagnostics, technological advancements in testing solutions, and increasing healthcare expenditure are fostering market growth.

Based on product and service, the allergy diagnostics market is segmented into instruments, consumables, and services. The services segment accounted for a significant USD 2.8 billion in 2024 and is expected to witness robust growth through 2034. The demand for allergy diagnostic services is propelled by the rising number of patients seeking clinical evaluations for various allergic reactions. Services such as test administration, laboratory analysis, and result interpretation are increasingly sought after to manage the growing burden of allergies. Further, partnerships between hospitals and specialized diagnostic laboratories are supporting the growth of this segment as healthcare providers seek to offer comprehensive allergy testing services to improve patient outcomes.

By test type, the in vivo segment of the allergy diagnostics market includes skin prick tests (SPT), intradermal tests, and patch tests. The segment is projected to reach USD 8.2 billion by 2034, owing to the widespread use of skin prick tests, which remain a gold standard for allergy detection due to their high sensitivity, rapid results, and cost-effectiveness. In vivo tests provide real-time assessment of allergic reactions, offering immediate insights for clinicians to determine treatment pathways. The continued development of minimally invasive and patient-friendly testing methodologies is expected to bolster segment growth further.

By allergen, the market is segmented into food allergens, inhaled allergens, drug allergens, and others. Among these, the inhaled allergens segment is forecasted to reach USD 7 billion by 2034. The surge in respiratory allergic conditions, including asthma, allergic rhinitis, and sinusitis, is a key driver. Pollen, dust mites, mold spores, and pet dander are among the primary inhaled allergens tested through diagnostic solutions. Increasing exposure to environmental pollutants and urbanization has escalated the demand for inhaled allergen diagnostics, especially in developed and urban settings.

Based on end-use, the allergy diagnostics market is segmented into hospital-based laboratories, diagnostic laboratories, academic research institutes, and others. The hospital-based laboratories segment dominated the market in 2024 and is projected to exceed USD 7.1 billion by 2034. The growth of this segment is attributed to increasing hospital admissions related to severe allergic reactions, such as anaphylaxis and asthma exacerbations. Hospital laboratories are well-equipped to conduct various allergy diagnostics, including in vivo and in vitro tests, often integrating them into routine diagnostic workflows. Moreover, hospital-based labs facilitate quick turnaround times for allergy testing, supporting timely intervention and treatment for patients, thus enhancing their adoption and market penetration.

Geographically, North America led the global allergy diagnostics market in 2024 and is anticipated to surpass USD 5.2 billion by 2034, fueled by rising allergic disease prevalence, advanced healthcare infrastructure, and growing adoption of sophisticated diagnostic technologies. The U.S. and Canada are at the forefront due to high awareness, significant investments in healthcare, and increasing collaborations between diagnostic companies and healthcare providers. Additionally, favorable reimbursement policies and continuous advancements in diagnostic technologies, such as molecular diagnostics and CRD, are further strengthening regional market growth.